CAMBRIDGE, Mass., May 26, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the closing of its underwritten public offering of 8,337,500 shares of its common stock at the public offering price of $19.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,087,500 additional shares of common stock.
Goldman, Sachs & Co. and J.P. Morgan acted as joint book-running managers for the offering. Stifel acted as lead manager.
The offering was made pursuant to an effective shelf registration statement on Form S-3 that was initially filed with the U.S. Securities and Exchange Commission (SEC) on April 30, 2013. A final prospectus supplement has been filed with the SEC and forms a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained by contacting Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or e-mail at email@example.com or J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204 or e-mail at firstname.lastname@example.org.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.